Blood Test Breakthrough: New Alzheimer’s Disease Diagnostics Offer Hope for Earlier Detection and Treatment
Table of Contents
A new era in Alzheimer’s disease (AD) diagnosis is dawning, with the US Food and Drug Management (FDA) recently clearing the frist blood-based biomarker tests designed to aid in assessment. For decades, diagnosing AD has relied on specialist memory clinics, expensive neuroimaging, or invasive cerebrospinal fluid (CSF) testing – a paradigm that is now poised for a significant shift. “Blood-based biomarkers for Alzheimer’s disease are probably the most crucial breakthrough in 20 years,” stated a leading researcher at the University of Edinburgh.
From Specialist Diagnostics to Accessible Blood Draws
In October 2025, the FDA authorized Roche’s Elecsys pTau181 assay, following the approval of Fujirebio’s Lumipulse G pTau217/β-amyloid 1-42 plasma ratio test earlier that year in May.Both assays identify proteins linked to AD pathology directly in plasma, presenting a less invasive and more accessible alternative to traditional methods like positron emission tomography (PET) imaging or lumbar puncture.
The ability to diagnose AD accurately and at an earlier stage has become increasingly urgent with the emergence of disease-modifying therapies. These treatments, including monoclonal antibodies targeting amyloid such as lecanemab and donanemab, can slow neurodegeneration but do not reverse it, making timely intervention crucial. They are most effective when administered before substantial neuronal loss occurs and require biologically confirmed AD pathology for patient eligibility. “Those therapeutics are quite precisely targeting a particular biology,” one expert explained, “But with disease-modifying therapies, you have to know you have the disease first.”
Distinct Assays for Different Clinical Needs
While often discussed together, the two FDA-cleared assays serve distinct clinical purposes and target different proteins. Roche’s Elecsys measures the level of tau protein phosphorylated at amino acid 181 (pTau181) in plasma. A multi-center study involving 312 participants demonstrated the assay’s ability to rule out AD with a negative predictive value of 97.9%.The FDA clearance specifies its use as an aid in assessing adults aged 55 and older presenting with cognitive decline symptoms, with results interpreted alongside other clinical facts. This marks the first AD blood test approved for use in primary care settings.
Fujirebio’s Lumipulse assay, conversely, measures both pTau217 and a β-amyloid peptide (amino acids 1-42) and calculates their ratio, correlating with the presence of amyloid plaques in the brain. This test is intended for patients presenting at specialized care facilities with signs of cognitive decline. A clinical study of 499 patients showed that 91.7% of those with positive results had amyloid pathology confirmed by PET or CSF testing, while 97.3% of those with negative results were amyloid negative. Though, approximately 20% of patients received indeterminate results.
A consultant at the Mayo Clinic emphasized the importance of this distinction. “The Roche test is best considered a rule-out or screening test,” she explained. “Its reported positive predictive value is around 22%, meaning most positive results require confirmatory testing with PET or CSF biomarkers.” The Fujirebio assay, she added, fun
Reshaping Clinical Trials and Expanding Access
Blood biomarkers are already transforming clinical trials for AD. “They’ve turned a shot in the dark into a shot on goal,” saeid a neurologist from the University of Nevada, Las Vegas. “Before them, we often didn’t know which trial patients truly had Alzheimer’s.” FDA-cleared blood tests could dramatically expand trial access,particularly for individuals in underserved or impoverished regions who may lack access to PET or CSF testing.
However,recent data presented at the 2025 Clinical Trials on Alzheimer’s Disease meeting in Boston underscored the need for continued validation. Findings suggested higher-than-expected false positive rates for the Lumipulse assay in certain patient cohorts, highlighting the importance of independently validating test performance in real-world settings, even for FDA-cleared tests.
